Paid Clinical Trials in District of Columbia

District of Columbia has 904 paid clinical trials enrolling now across cities including Washington D.C., Georgetown and Multiple Locations. Search by condition, age, or phase to find compensated research studies accepting participants near you.

Both patients and healthy volunteers may qualify. Most studies offer compensation for time and travel.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

State

City

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

904 clinical trials

↓ Download CSV

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

for AL Amyloidosis

117 locations incl. Goodyear

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06022939·Phase 3·Recruiting

Apply to this trial

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

for Carcinoma, Pancreatic Ductal

26 locations incl. Fayetteville

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06447662·Phase 1·Recruiting

Apply to this trial

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

for Stage II Nasopharyngeal Carcinoma AJCC v8

Drug: Nivolumab

76 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 21

Code: NCT06064097·Phase 2·Recruiting

Apply to this trial

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

for Cardiovascular Risk

Drug: Ziltivekimab

208 locations incl. Alexander City

Sponsor: Novo Nordisk A/S

Sex: All·Age: 18+

Code: NCT06118281·Phase 3·Recruiting

Apply to this trial

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

for Generalized Myasthenia Gravis

21 locations incl. Phoenix

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Sex: All·Age: 18+

Code: NCT06463587·Phase 3·Recruiting

Apply to this trial

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

for Transthyretin Amyloidosis

30 locations incl. La Jolla

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT06465810·Recruiting

Apply to this trial

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

for Head and Neck Squamous Cell Carcinoma

Drug: Petosemtamab

61 locations incl. Mobile

Sponsor: Merus B.V.

Sex: All·Age: 18+

Code: NCT06496178·Phase 3·Recruiting

Apply to this trial

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging

for Stroke

13 locations incl. Birmingham

Sponsor: Yale University

Sex: All·Age: 18+

Code: NCT05907629·Recruiting

Apply to this trial

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

for Advanced Esophageal Adenocarcinoma

Drug: Nivolumab

371 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06203600·Phase 2, Phase 3·Recruiting

Apply to this trial

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

for Colorectal Cancer

13 locations incl. Los Angeles

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06428409·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

for Polymyositis, Dermatomyositis

43 locations incl. Phoenix

Sponsor: AstraZeneca

Sex: All·Age: 18 - 75

Code: NCT06455449·Phase 3·Recruiting

Apply to this trial

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

for Large B-cell Lymphoma

60 locations incl. Gilbert

Sponsor: Allogene Therapeutics

Sex: All·Age: 18+

Code: NCT06500273·Phase 2·Recruiting

Apply to this trial

A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

for Parkinson Disease

27 locations incl. Irvine

Sponsor: AskBio Inc

Sex: All·Age: 45 - 75

Code: NCT06285643·Phase 2·Recruiting

Apply to this trial

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

for Non-small Cell Lung Cancer

20 locations incl. San Antonio

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06422143·Phase 3·Recruiting

Apply to this trial

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

for Advanced Melanoma

Drug: Nivolumab

37 locations incl. Tucson

Sponsor: Immunocore Ltd

Sex: All·Age: 18+

Code: NCT06112314·Phase 3·Recruiting

Apply to this trial

Prospective Clinical Assessment Study in Children With Hypochondroplasia

for Hypochondroplasia

8 locations incl. Oakland

Sponsor: QED Therapeutics, a BridgeBio company

Sex: All·Age: 30 Months - 16

Code: NCT06410976·Recruiting

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

for Crohn's Disease

Drug: Tulisokibart

87 locations incl. Dothan

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 16 - 80

Code: NCT06430801·Phase 3·Recruiting

Apply to this trial

Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents

for Sexually Transmitted Diseases

1 location in Washington D.C.

Sponsor: Children's National Research Institute

Sex: All·Age: 15 - 21

Code: NCT04372485·Recruiting

Apply to this trial

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for Myelofibrosis

Drug: Ruxolitinib

58 locations incl. Birmingham

Sponsor: Kartos Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06479135·Phase 3·Recruiting

Apply to this trial

Patient Navigation for Colorectal Cancer Screening

for Colorectal Cancer Screening

15 locations incl. Washington D.C.

Sponsor: Medstar Health Research Institute

Sex: All·Age: 45 - 75

Code: NCT06401174·Enrolling By Invitation

Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease

for Sickle Cell Disease (SCD)

31 locations incl. Birmingham

Sponsor: University of Rochester

Sex: All·Age: 3 - 20

Code: NCT06941389·Recruiting

Apply to this trial

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

for Pediatric

Drug: Aficamten

26 locations incl. Phoenix

Sponsor: Cytokinetics

Sex: All·Age: 12 - 17

Code: NCT06412666·Phase 2, Phase 3·Recruiting

Apply to this trial

Advancing Transplantation Outcomes in Children

for Kidney Transplant

20 locations incl. Birmingham

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Sex: All·Age: 13 - 20

Code: NCT06055608·Phase 2·Recruiting

Apply to this trial

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

for Breast Neoplasms

82 locations incl. Tucson

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT06157892·Phase 2·Recruiting

Apply to this trial

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

for Focal Epilepsy

Drug: BHV-7000

65 locations incl. Birmingham

Sponsor: Biohaven Therapeutics Ltd.

Sex: All·Age: 18 - 75

Code: NCT06309966·Phase 2, Phase 3·Recruiting

Apply to this trial

Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer

for Prostate Cancer

5 locations incl. Washington D.C.

Sponsor: Adam S. Kibel, MD

Sex: Male·Age: 40 - 69·Accepts healthy volunteers

Code: NCT06398639·Recruiting

Apply to this trial

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

for Idiopathic Pulmonary Fibrosis

Drug: Nerandomilast

58 locations incl. Birmingham

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06238622·Phase 3·Recruiting

Apply to this trial

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

Drug: Osimertinib

36 locations incl. Fountain Valley

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06350097·Phase 3·Recruiting

Apply to this trial

Focused Ultrasound for the Complex Patient

for Opioid Use Disorder

1 location in Washington D.C.

Sponsor: Washington D.C. Veterans Affairs Medical Center

Sex: All·Age: 18 - 75·Accepts healthy volunteers

Code: NCT06453109·Recruiting

Apply to this trial

A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

for Thymoma

4 locations incl. Palo Alto

Sponsor: Georgetown University

Sex: All·Age: 18+

Code: NCT06248515·Phase 2·Recruiting

Apply to this trial

Protocol CAUSE-03 / CHEETAH

for Asthma

8 locations incl. Aurora

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Sex: All·Age: 6 - 17·Accepts healthy volunteers

Code: NCT06136091·Recruiting

Apply to this trial

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

for Solid Tumor

17 locations incl. Duarte

Sponsor: Biohaven Therapeutics Ltd.

Sex: All·Age: 18+

Code: NCT06384807·Phase 1, Phase 2·Recruiting

Apply to this trial

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

for Ganglioneuroblastoma, Nodular

156 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 30

Code: NCT06172296·Phase 3·Recruiting

Apply to this trial

Pre-operative Hypofractionated Proton Therapy

for Soft Tissue Sarcoma

1 location in Washington D.C.

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sex: All·Age: 18+

Code: NCT05917301·Recruiting

Apply to this trial

Platform Clinical Study for Conquering Scleroderma

for Interstitial Lung Disease Due to Systemic Disease

34 locations incl. Birmingham

Sponsor: Scleroderma Research Foundation, Inc.

Sex: All·Age: 18+

Code: NCT06195072·Phase 2·Recruiting

Apply to this trial

Vosoritide for Short Stature in Turner Syndrome

for Turner Syndrome

Drug: Vosoritide

1 location in Washington D.C.

Sponsor: Roopa Kanakatti Shankar, MBBS, MS

Sex: Female·Age: 3 - 11

Code: NCT05849389·Phase 2·Recruiting

Apply to this trial

Technical Development of Cardiovascular Magnetic Resonance Imaging

for Cardiovascular Disease

2 locations incl. Washington D.C.

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Sex: All·Age: 18 - 100·Accepts healthy volunteers

Code: NCT04927429·Recruiting

Apply to this trial

Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody

for Sickle Cell Disease

1 location in Washington D.C.

Sponsor: Children's National Research Institute

Sex: All·Age: 2 - 25

Code: NCT06358638·Phase 2·Recruiting

Apply to this trial

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

for Prostate Cancer

44 locations incl. Homewood

Sponsor: Curium US LLC

Sex: Male·Age: 18+

Code: NCT06235151·Phase 3·Recruiting

Apply to this trial

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

for Recurrent Langerhans Cell Histiocytosis

104 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 180 Days - 22

Code: NCT05828069·Phase 2·Recruiting

Apply to this trial